- Report
- January 2024
- 260 Pages
Global
From €2193EUR$2,450USD£1,868GBP
- Report
- March 2024
- 128 Pages
Global
From €4163EUR$4,650USD£3,546GBP
- Report
- February 2024
- 442 Pages
Global
From €4163EUR$4,650USD£3,546GBP
- Report
- August 2023
- 141 Pages
Global
From €4163EUR$4,650USD£3,546GBP
- Report
- July 2023
- 138 Pages
Global
From €4163EUR$4,650USD£3,546GBP
- Report
- February 2022
- 312 Pages
Global
From €2686EUR$3,000USD£2,288GBP
- Report
- July 2020
- 100 Pages
Global
From €3290EUR$3,675USD£2,802GBP
- Report
- August 2022
- 382 Pages
Global
From €3133EUR$3,500USD£2,669GBP
- Report
- November 2023
- 150 Pages
Global
From €5326EUR$5,950USD£4,537GBP
- Report
- June 2023
- 65 Pages
Global
From €4431EUR$4,950USD£3,774GBP
- Report
- May 2024
- 129 Pages
Global
From €5818EUR$6,499USD£4,956GBP
- Report
- September 2023
- 200 Pages
Global
From €5326EUR$5,950USD£4,537GBP
- Report
- May 2023
- 180 Pages
Global
From €5326EUR$5,950USD£4,537GBP
- Report
- May 2023
- 180 Pages
Global
From €5326EUR$5,950USD£4,537GBP
- Report
- March 2023
- 180 Pages
Global
From €5326EUR$5,950USD£4,537GBP
- Report
- January 2023
- 217 Pages
Global
From €5326EUR$5,950USD£4,537GBP
- Report
- September 2022
- 62 Pages
Global
From €4431EUR$4,950USD£3,774GBP
- Report
- January 2023
- 103 Pages
Global
From €4431EUR$4,950USD£3,774GBP
- Report
- November 2022
- 65 Pages
Global
From €4431EUR$4,950USD£3,774GBP
- Report
- November 2021
- 88 Pages
Global
From €4431EUR$4,950USD£3,774GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more